Bronchitol (Pharmaxis) is filed at the FDA for the treatment of Cystic Fibrosis

Pharmaxis has submitted a new drug application (NDA) to the FDA for Bronchitol, a formulation of mannitol administered as a dry powder in a hand?held inhaler, as a treatment for patients with Cystic Fibrosis. Bronchitol, which is used to clear mucus � a major source of lung infections � improve lung function and reduce exacerbations in patients with cystic fibrosis, already is approved in Europe and Australia.